Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Glioma × Naltrexone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Obesity 3 Breast Neoplasms 3 Prostatic Neoplasms 2 Overweight 2 Melanoma 2 Skin Neoplasms 1 Metabolic Syndrome 1 Kidney Neoplasms 1 Inflammation 1 Glioma 1 Glioblastoma 1 Dyslipidemias 1 Carcinoma, Lobular 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

Temozolomide 99 Magnetic Resonance Spectroscopy 46 Bevacizumab 46 Radiotherapy 41 Irinotecan 23 Blood Specimen Collection 15 Aminolevulinic Acid 15 Surgical Procedures, Operative 13 Radiation 13 Carboplatin 13 Nivolumab 12 fluorodopa F 18 10 Radiotherapy, Intensity-Modulated 10 Radiosurgery 10 Carmustine 10 pembrolizumab 9 Topotecan 9 Surveys and Questionnaires 8 Specimen Handling 8 Magnetic Resonance Imaging 8 Erlotinib Hydrochloride 8 Biopsy 8 poly ICLC 7 Standard of Care 7 Filgrastim 7 Everolimus 7 Etoposide 7 Drug Therapy 7 Cyclophosphamide 7 ribociclib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed

110 enrolled 9 charts

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡